company background image
KRTX

Karuna Therapeutics NasdaqGM:KRTX Stock Report

Last Price

US$235.31

Market Cap

US$8.1b

7D

2.7%

1Y

91.2%

Updated

01 Dec, 2022

Data

Company Financials +
KRTX fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

KRTX Stock Overview

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions.

Karuna Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Karuna Therapeutics
Historical stock prices
Current Share PriceUS$235.31
52 Week HighUS$278.25
52 Week LowUS$92.26
Beta1.14
1 Month Change7.28%
3 Month Change-8.01%
1 Year Change91.23%
3 Year Change237.90%
5 Year Changen/a
Change since IPO1,075.38%

Recent News & Updates

Karuna Therapeutics, Inc. (NASDAQ:KRTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Nov 06
Karuna Therapeutics, Inc. (NASDAQ:KRTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Recent updates

Karuna Therapeutics, Inc. (NASDAQ:KRTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Nov 06
Karuna Therapeutics, Inc. (NASDAQ:KRTX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Best Performing Stocks

Sep 23
Best Performing Stocks

Karuna Therapeutics (NASDAQ:KRTX) Is In A Good Position To Deliver On Growth Plans

May 10
Karuna Therapeutics (NASDAQ:KRTX) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Karuna Therapeutics (NASDAQ:KRTX) Will Use Its Cash Wisely

Jan 24
We're Hopeful That Karuna Therapeutics (NASDAQ:KRTX) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Karuna Therapeutics' (NASDAQ:KRTX) Cash Burn Situation

Oct 11
Here's Why We're Not Too Worried About Karuna Therapeutics' (NASDAQ:KRTX) Cash Burn Situation

We're Not Very Worried About Karuna Therapeutics' (NASDAQ:KRTX) Cash Burn Rate

May 18
We're Not Very Worried About Karuna Therapeutics' (NASDAQ:KRTX) Cash Burn Rate

Should You Take Comfort From Insider Transactions At Karuna Therapeutics, Inc. (NASDAQ:KRTX)?

Feb 02
Should You Take Comfort From Insider Transactions At Karuna Therapeutics, Inc. (NASDAQ:KRTX)?

Companies Like Karuna Therapeutics (NASDAQ:KRTX) Are In A Position To Invest In Growth

Dec 11
Companies Like Karuna Therapeutics (NASDAQ:KRTX) Are In A Position To Invest In Growth

Shareholder Returns

KRTXUS BiotechsUS Market
7D2.7%2.3%1.5%
1Y91.2%-10.2%-14.8%

Return vs Industry: KRTX exceeded the US Biotechs industry which returned -15.2% over the past year.

Return vs Market: KRTX exceeded the US Market which returned -18.9% over the past year.

Price Volatility

Is KRTX's price volatile compared to industry and market?
KRTX volatility
KRTX Average Weekly Movement5.8%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.5%
10% least volatile stocks in US Market3.3%

Stable Share Price: KRTX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: KRTX's weekly volatility has decreased from 13% to 6% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2009118Steve Paulhttps://www.karunatx.com

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates.

Karuna Therapeutics, Inc. Fundamentals Summary

How do Karuna Therapeutics's earnings and revenue compare to its market cap?
KRTX fundamental statistics
Market CapUS$8.09b
Earnings (TTM)-US$228.08m
Revenue (TTM)US$42.32m

191.1x

P/S Ratio

-35.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
KRTX income statement (TTM)
RevenueUS$42.32m
Cost of RevenueUS$0
Gross ProfitUS$42.32m
Other ExpensesUS$270.41m
Earnings-US$228.08m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-6.64
Gross Margin100.00%
Net Profit Margin-538.91%
Debt/Equity Ratio0%

How did KRTX perform over the long term?

See historical performance and comparison